Daymark Health just lit up the oncology space with a Series A that matters, $20M to scale a model built for reality, not theory. Born in Philly and led by Dr. Justin Bekelman, MD, the oncologist who once ran Penn Medicine’s Center for Cancer Care Innovation, Daymark was built to untangle cancer’s messy care journey. Alongside co-founders Robert Pahlavan and Jonathan Rhodes, the team designed a system where patients get tech-enabled, in home, and virtual support wrapped around their existing oncology teams.
The investors lining up aren’t tourists. Healthier Capital, founded by Amir Dan Rubin of One Medical fame, called the play. Blue Venture Fund brought the weight of 36 BCBS companies and the Association behind a $1.2B vehicle. Yosemite Ventures, Maverick Ventures, and Oncology Ventures doubled down after the $11.5M seed back in April. That seed was the spark, this $20M is the accelerant.
Execution is already on display. Since launch in Q2, Daymark has delivered supportive care to 2,500+ patients through partnerships with health plans and community clinicians. Patients get 24/7 navigation, symptom management, and mental health support via hybrid tech, home visits, and integrated workflows. Under the hood sits a HIPAA-compliant, cloud-native platform on AWS, wired with EMR integrations and decision support algorithms. The tech hums, but the differentiator is human, nurse practitioners, RNs, social workers, and HealthPartners walking into homes while algorithms flag risks in real time.
Strategically, Daymark played the long game. They didn’t raise on concept. They raised after proving traction with a major Northeast health plan and locking in Blue Cross & Blue Shield of Rhode Island. That sequencing is a business lesson; investors back proof, not just potential. Daymark stacked early wins, then scaled the vision.
The path forward is aggressive but calculated. By Q4 2026, they plan to be active in 10 new states, integrate with 5 more EMR systems, and add 3 payer networks. Product roadmap, a predictive analytics module in early 2026, a patient app with adherence tracking midyear. Hiring, 60+ clinicians plus data science and engineering talent. Accreditation and IP filings sit on deck too. Every move signals permanence, not experimentation.
The name Daymark fits. A daymark is a beacon, guiding ships through rough waters by daylight. For patients with cancer, this company is building the same, a visible, reliable guide through turbulence, anchored in both community and tech. Big congrats to Justin Bekelman, Robert Pahlavan, and Jonathan Rhodes. And props to Healthier Capital, Blue Venture Fund, Yosemite Ventures, Maverick Ventures, and Oncology Ventures for backing a model that could become the reference point for value-based oncology care nationwide.
